drugset / Trial / NCT00413790

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

NCT00413790

Phase 4 Completed 162 enrolled Novartis Procter and Gamble · collab
RandomizedCrossoverDouble-blindTreatment

Summary

This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older

Timeline

Start
2006-11
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Darifenacin Small molecule 15 mg
Comparator Tolterodine Small molecule 4 mg

Indications

No indication recorded.